Pharmaceuticals - Brazil

  • Brazil
  • The revenue generated in the Pharmaceuticals market in Brazil is projected to reach €18.80bn in 2024.
  • Among the various markets, Oncology Drugs is expected to be the largest, with a projected market volume of €3.20bn in 2024.
  • Looking ahead, the revenue is anticipated to grow at an annual rate of 4.71% (CAGR 2024-2029), resulting in a market volume of €23.67bn by 2029.
  • In a global comparison, it is noteworthy that United States is expected to generate the highest revenue, amounting to €578.50bn in 2024.
  • Brazil's pharmaceutical market is experiencing a surge in demand for generic drugs due to increasing healthcare costs.

Key regions: United States, China, Germany, Japan, Europe

 
Marché
 
Région
 
Comparaison de régions
 
Monnaie
 

Analyst Opinion

The Pharmaceuticals market in Brazil has been experiencing significant growth in recent years.

Customer preferences:
Brazil has a large population, and as such, there is a high demand for pharmaceutical products. Customers in Brazil tend to value affordable healthcare, which has led to an increase in the consumption of generic drugs. Additionally, the aging population in Brazil has contributed to the growth of the pharmaceutical market, as older individuals tend to require more medication.

Trends in the market:
One major trend in the Brazilian pharmaceutical market is the increasing demand for generic drugs. This trend is driven by the country's universal healthcare system, which prioritizes cost-effective treatments. Another trend is the growing focus on research and development, as Brazilian pharmaceutical companies seek to innovate and bring new products to market. Additionally, there has been a rise in mergers and acquisitions, as companies look to expand their market share and gain a competitive edge.

Local special circumstances:
Brazil has a complex regulatory environment for pharmaceuticals, which can pose challenges for companies looking to enter the market. Additionally, the country has a high tax burden, which can impact the affordability of drugs for consumers. Another local circumstance is the prevalence of counterfeit drugs, which can be a significant issue in Brazil and can impact consumer trust in the pharmaceutical industry.

Underlying macroeconomic factors:
Brazil is the largest economy in Latin America, and as such, has a significant impact on the region's pharmaceutical market. The country has experienced economic instability in recent years, which has led to fluctuations in the pharmaceutical market. Additionally, Brazil has a large and growing middle class, which has contributed to the growth of the pharmaceutical market. Finally, the country's universal healthcare system plays a significant role in shaping the pharmaceutical market, as it prioritizes cost-effective treatments and drives demand for generic drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

Vue d’ensemble

  • Revenue
  • Analyst Opinion
  • Next generation therapy
  • Global Comparison
  • Methodology
  • Key Market Indicators
Veuillez patienter

Contact

Des questions ? Nous nous ferons un plaisir de vous aider.
Statista Locations
Contact Camille Dubois
Camille Dubois
Customer Relations

Lun - Ven, 9:00 - 18:00 h (EST)

Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (États-Unis)

Lun - Ven, 9:00 - 18:00 h (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asie)

Lun - Ven, 9:00 - 17:00 h (SGT)

Contact Ayana Mizuno
Ayana Mizuno
Junior Business Development Manager– Contact (Asie)

Lun - Ven, 10:00 - 18:00 h (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Lun - Ven, 9:00 - 18:00 h (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Amérique latine)

Lun - Ven, 9:00 - 18:00 h (EST)